Show simple item record

dc.contributor.authorWest, Catharine M L
dc.contributor.authorMcKay, Michael J
dc.contributor.authorHölscher, Tobias
dc.contributor.authorBaumann, Michael
dc.contributor.authorStratford, Ian J
dc.contributor.authorBristow, Robert G
dc.contributor.authorIwakawa, Mayumi
dc.contributor.authorImai, Takashi
dc.contributor.authorZingde, Surekha M
dc.contributor.authorAnscher, Mitchell S
dc.contributor.authorBourhis, Jean
dc.contributor.authorBegg, Adrian C
dc.contributor.authorHaustermans, Karin
dc.contributor.authorBentzen, Soren M
dc.contributor.authorHendry, Jolyon H
dc.date.accessioned2009-08-10T10:21:17Z
dc.date.available2009-08-10T10:21:17Z
dc.date.issued2005-08-01
dc.identifier.citationMolecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. 2005, 62 (5):1264-73 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016
dc.identifier.pmid16029781
dc.identifier.doi10.1016/j.ijrobp.2005.05.001
dc.identifier.urihttp://hdl.handle.net/10541/76801
dc.description.abstractPURPOSE: There is increasing interest in radiogenomics and the characterization of molecular profiles that predict normal tissue and tumor radioresponse. A meeting in Amsterdam was organized by the International Atomic Energy Agency to discuss this topic on an international basis. METHODS AND MATERIALS: This report is not completely exhaustive, but highlights some of the ongoing studies and new initiatives being carried out worldwide in the banking of tumor and normal tissue samples underpinning the development of molecular marker profiles for predicting patient response to radiotherapy. It is generally considered that these profiles will more accurately define individual or group radiosensitivities compared with the nondefinitive findings from the previous era of cellular-based techniques. However, so far there are only a few robust reports of molecular markers predicting normal tissue or tumor response. RESULTS: Many centers in different countries have initiated tissue and tumor banks to store samples from clinical trials for future molecular profiling analysis, to identify profiles that predict for radiotherapy response. The European Society for Therapeutic Radiology and Oncology GENEtic pathways for the Prediction of the effects of Irradiation (GENEPI) project, to store, document, and analyze sample characteristics vs. response, is the most comprehensive in this regard. CONCLUSIONS: The next 5-10 years are likely to see the results of these and other correlative studies, and promising associations of profiles with response should be validated in larger definitive trials.
dc.language.isoenen
dc.subjectCanceren
dc.subjectTumour Markersen
dc.subject.meshDatabases, Factual
dc.subject.meshGenetic Markers
dc.subject.meshHealth Planning Guidelines
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshRadiation Injuries
dc.subject.meshRadiation Tolerance
dc.subject.meshTissue Banks
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Markers, Biological
dc.titleMolecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Radiation Oncology, The University of Manchester, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen
html.description.abstractPURPOSE: There is increasing interest in radiogenomics and the characterization of molecular profiles that predict normal tissue and tumor radioresponse. A meeting in Amsterdam was organized by the International Atomic Energy Agency to discuss this topic on an international basis. METHODS AND MATERIALS: This report is not completely exhaustive, but highlights some of the ongoing studies and new initiatives being carried out worldwide in the banking of tumor and normal tissue samples underpinning the development of molecular marker profiles for predicting patient response to radiotherapy. It is generally considered that these profiles will more accurately define individual or group radiosensitivities compared with the nondefinitive findings from the previous era of cellular-based techniques. However, so far there are only a few robust reports of molecular markers predicting normal tissue or tumor response. RESULTS: Many centers in different countries have initiated tissue and tumor banks to store samples from clinical trials for future molecular profiling analysis, to identify profiles that predict for radiotherapy response. The European Society for Therapeutic Radiology and Oncology GENEtic pathways for the Prediction of the effects of Irradiation (GENEPI) project, to store, document, and analyze sample characteristics vs. response, is the most comprehensive in this regard. CONCLUSIONS: The next 5-10 years are likely to see the results of these and other correlative studies, and promising associations of profiles with response should be validated in larger definitive trials.


Files in this item

This item appears in the following Collection(s)

Show simple item record